-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompilationFan Dongdong
Takeda announced in an open letter to the Hypoparathyroidism Association and the broader hypoparathyroidism patients and the medical community that 100 micrograms of Natpara may be interrupted as early as this week due to shortage of supply.
The company’s U.
Takeda Natpara injection is a recombinant human protein with a full-length 84 amino acid sequence of endogenous parathyroid hormone (PTH).
In 2019, Takeda announced the recall of all injection dosage specifications of Natpara injection in the US market.
In addition to the recall, manufacturing delays have also delayed the company's previously anticipated timetable.
Reference source:
1.
2.